KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Inventory (2016 - 2025)

Emergent BioSolutions' Inventory history spans 16 years, with the latest figure at $343.4 million for Q4 2025.

  • For Q4 2025, Inventory rose 10.17% year-over-year to $343.4 million; the TTM value through Dec 2025 reached $343.4 million, up 10.17%, while the annual FY2025 figure was $343.4 million, 10.17% up from the prior year.
  • Inventory reached $343.4 million in Q4 2025 per EBS's latest filing, down from $356.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $528.2 million in Q3 2022 to a low of $311.7 million in Q4 2024.
  • Average Inventory over 5 years is $362.5 million, with a median of $352.4 million recorded in 2022.
  • Peak YoY movement for Inventory: surged 63.85% in 2021, then plummeted 32.96% in 2023.
  • A 5-year view of Inventory shows it stood at $344.5 million in 2021, then increased by 1.8% to $350.7 million in 2022, then decreased by 6.22% to $328.9 million in 2023, then fell by 5.23% to $311.7 million in 2024, then rose by 10.17% to $343.4 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Inventory are $343.4 million (Q4 2025), $356.3 million (Q3 2025), and $338.6 million (Q2 2025).